Alt-protein
-
DATABASE (44)
-
ARTICLES (132)
Lever VC was founded in 2018 by Nick Cooney, an early investor of Beyond Meat and Memphis Meats. He is also the co-founder of Good Food Institute. Lever has currently invested in 14 startups from the US, Europe, Asia and Latin America.Focused on investments in early-stage alternative protein companies, the firm announced the first close of its Lever VC Fund I in August 2020, with its fourth close at $46m in April 2021. The final close will be completed by June 2021. Investors in the fund include NFL and NBA athletes, British nobility, food businesses, alt-protein companies and family offices as limited partners.In June 2020, Lever launched a $28m joint investment fund and accelerator to invest in Chinese plant-based and cell-cultivated meat and dairy companies. The Lever China Alternative Protein Fund will invest RMB 40m in alt-protein companies in mainland China over the next four years.
Lever VC was founded in 2018 by Nick Cooney, an early investor of Beyond Meat and Memphis Meats. He is also the co-founder of Good Food Institute. Lever has currently invested in 14 startups from the US, Europe, Asia and Latin America.Focused on investments in early-stage alternative protein companies, the firm announced the first close of its Lever VC Fund I in August 2020, with its fourth close at $46m in April 2021. The final close will be completed by June 2021. Investors in the fund include NFL and NBA athletes, British nobility, food businesses, alt-protein companies and family offices as limited partners.In June 2020, Lever launched a $28m joint investment fund and accelerator to invest in Chinese plant-based and cell-cultivated meat and dairy companies. The Lever China Alternative Protein Fund will invest RMB 40m in alt-protein companies in mainland China over the next four years.
With a 55-tone capacity to produce fungi-based proteins annually, Mycorena’s Gothenburg facility will showcase its mycoprotein R&D and spur commercial expansion across Europe.
With a 55-tone capacity to produce fungi-based proteins annually, Mycorena’s Gothenburg facility will showcase its mycoprotein R&D and spur commercial expansion across Europe.
Bånt AB is the investment vehicle of Karl Sverker Forsén based in Luleå, a coastal city in Swedish Lapland. In May 2020, the Swedish family office invested in a Gothenburg startup Mycorena, a biotech that produces mycoproteins through fermentation. The fungi-based protein can be used as an alt-protein ingredient instead of traditional plant-based food components.
Bånt AB is the investment vehicle of Karl Sverker Forsén based in Luleå, a coastal city in Swedish Lapland. In May 2020, the Swedish family office invested in a Gothenburg startup Mycorena, a biotech that produces mycoproteins through fermentation. The fungi-based protein can be used as an alt-protein ingredient instead of traditional plant-based food components.
WWF-backed biotech Oceanium has developed a biorefinery that transforms seaweed into alt-proteins and compostable packaging that will soon be launched commercially.
WWF-backed biotech Oceanium has developed a biorefinery that transforms seaweed into alt-proteins and compostable packaging that will soon be launched commercially.
E²JDJ was founded in New Orleans in 2020 with an agtech and foodtech focus, including in the areas of cellular agriculture and synthetic biology. It has six startups in its portfolio and makes diverse investments. Its most recent disclosed investment was in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions.
E²JDJ was founded in New Orleans in 2020 with an agtech and foodtech focus, including in the areas of cellular agriculture and synthetic biology. It has six startups in its portfolio and makes diverse investments. Its most recent disclosed investment was in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions.
CEO and founder of Mycorena
Ramkumar Nair graduated in biotechnology at the Cochin University of Science and Technology in Kerala before going to Sweden for postgrad studies in 2013.During his PhD in industrial biotechnology at the University of Borås, he embarked on a research project to create fungi-based proteins from discarded sidestreams generated by food producers. After extensive research in 2017, he founded Mycorena in Gothenburg to produce mycoproteins using fermentation technology.The startup’s first commercial product, Promyc, is now being sold to global food companies as a more sustainable and nutritional alt-protein compared to traditional plant-based proteins.
Ramkumar Nair graduated in biotechnology at the Cochin University of Science and Technology in Kerala before going to Sweden for postgrad studies in 2013.During his PhD in industrial biotechnology at the University of Borås, he embarked on a research project to create fungi-based proteins from discarded sidestreams generated by food producers. After extensive research in 2017, he founded Mycorena in Gothenburg to produce mycoproteins using fermentation technology.The startup’s first commercial product, Promyc, is now being sold to global food companies as a more sustainable and nutritional alt-protein compared to traditional plant-based proteins.
CEO and founder of Plantruption
Jennifer O'Brien qualified as a financial advisor at University College Dublin in 2010. She started her banking career in 2007 at AIB where she spent six years working with SMEs and investments. In 2013, she joined KBC Bank Ireland as a restructures executive and went on to work as an asset manager at Link Asset Services in 2016. O’Brien also worked in asset management for two years at O’Dwyer Real Estate Management while completing an MBA at Trinity College Dublin. She left the realty company in 2019 to realize her dream to create alt-protein seafood using locally sourced seaweed.
Jennifer O'Brien qualified as a financial advisor at University College Dublin in 2010. She started her banking career in 2007 at AIB where she spent six years working with SMEs and investments. In 2013, she joined KBC Bank Ireland as a restructures executive and went on to work as an asset manager at Link Asset Services in 2016. O’Brien also worked in asset management for two years at O’Dwyer Real Estate Management while completing an MBA at Trinity College Dublin. She left the realty company in 2019 to realize her dream to create alt-protein seafood using locally sourced seaweed.
Founded in 2017 in Hong Kong, Happiness Capital invests in seed to growth stage companies in the US, Europe, Israel, and China, with a focus on issues affecting global happiness within the areas of citizen trust, food, health, climate change, and reduced inequalities. It hosts its own annual contest, the Super Happiness Challenge , a global open innovation contest to fund individuals and startups with ideas and new products or services that tapped into unmet needs to achieve happiness, with a possible $1m in total investment on offer. The VC currently has 37 startups in its portfolio, around half of which are in foodtech and agtech. Its most recent investments include leading the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions, and co-leading the $29m February 2021 Series A round of Israeli 3D printed alt-meat startup Redefine Meat.
Founded in 2017 in Hong Kong, Happiness Capital invests in seed to growth stage companies in the US, Europe, Israel, and China, with a focus on issues affecting global happiness within the areas of citizen trust, food, health, climate change, and reduced inequalities. It hosts its own annual contest, the Super Happiness Challenge , a global open innovation contest to fund individuals and startups with ideas and new products or services that tapped into unmet needs to achieve happiness, with a possible $1m in total investment on offer. The VC currently has 37 startups in its portfolio, around half of which are in foodtech and agtech. Its most recent investments include leading the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions, and co-leading the $29m February 2021 Series A round of Israeli 3D printed alt-meat startup Redefine Meat.
Based in London, CPT Capital is the venture arm of private equity pioneer Jeremy Coller's private family office. Coller is the founder of Europe’s first private equity for secondaries in 1990. The British philanthropist has also established several business schools and the Jeremy Coller Foundation that aims to eliminate factory farming. In 2017, CPT Capital was founded to disrupt the food industry with investments in the alt-protein sector to create the “future of food and materials” like plant-based, recombinant and cell-cultured proteins.
Based in London, CPT Capital is the venture arm of private equity pioneer Jeremy Coller's private family office. Coller is the founder of Europe’s first private equity for secondaries in 1990. The British philanthropist has also established several business schools and the Jeremy Coller Foundation that aims to eliminate factory farming. In 2017, CPT Capital was founded to disrupt the food industry with investments in the alt-protein sector to create the “future of food and materials” like plant-based, recombinant and cell-cultured proteins.
Mitchell Presser is a New York-based lawyer. He is currently co-chair of global law service Morrison & Foerster’s Global Corporate Department and a partner in the firm’s M&A and Private Equity group, advising on agriculture, amongst other areas. He previously was a founding partner of Paine Schwartz, a US-based $1.2 bn private equity firm specializing in sustainable food chain investing from 2006 to 2014. His sole disclosed angel investment to date was an undisclosed sum in the pre-seed funding of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions,
Mitchell Presser is a New York-based lawyer. He is currently co-chair of global law service Morrison & Foerster’s Global Corporate Department and a partner in the firm’s M&A and Private Equity group, advising on agriculture, amongst other areas. He previously was a founding partner of Paine Schwartz, a US-based $1.2 bn private equity firm specializing in sustainable food chain investing from 2006 to 2014. His sole disclosed angel investment to date was an undisclosed sum in the pre-seed funding of NovoNutrients, the US-based biotech producer of alt-protein from fermentation using CO2 and other emissions,
Chairman of the Board, co-founder, co-inventor of NovoNutrients
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
Russell J. Howard has been co-founder and chairman of the board at NovoNutrients, a San Francisco biotech manufacturer of alt-protein produced using fermentation and CO2, and the research company Oakbio, since the latter’s foundation in 2009. During this period, for a year, Howard also worked as head of commercial strategy at Genome.One, a genetics startup. Howard is also on the board of executives of two Australian pharma companies, Immutep and NeuClone. Previously, between 1997 and 2009, he was CEO at California-based Maxygen, dedicated to the commercialization of molecular breeding and gene shuffling in protein. The year before that, Howard was president and scientific director at global pharma giant GSK in Santa Clara, and between 1994 and 1996, he held the same position at AFFYMAX Research Institute, working on new drugs research. Howard also held long-term research positions, heading up the laboratory at Palo Alto’s DNAX Research Institute of Molecular & Cellular Biology for six years, and earlier spent nine years at Bethesda’s National Institute of Allergy and Infectious Diseases (NIAID) working on identifying new malarial pathogens. The doctor of biochemistry from the University of Melbourne has over 140 peer-reviewed publications. Following his studies, Howard spent three years undertaking postdoctoral research at Australia’s WEHI (formerly the Walter and Eliza Hall Institute of Medical Research).
San Francisco-based BOND is a spinoff of Kleiner Perkins and its original digital growth fund. BOND was launched in 2019, investing across market segments and geographies. To date, it has raised two funds totaling $3.3bn and currently has 32 portfolio companies. Its recent investments include Portuguese home physiotherapy tech SWORD, the world’s fastest-growing musculoskeletal solution, in June 2021 in a $85m Series C funding round; and co-leading the July 2021 $50m Series B round of US fungi-based alt-protein startup Meati Foods.
San Francisco-based BOND is a spinoff of Kleiner Perkins and its original digital growth fund. BOND was launched in 2019, investing across market segments and geographies. To date, it has raised two funds totaling $3.3bn and currently has 32 portfolio companies. Its recent investments include Portuguese home physiotherapy tech SWORD, the world’s fastest-growing musculoskeletal solution, in June 2021 in a $85m Series C funding round; and co-leading the July 2021 $50m Series B round of US fungi-based alt-protein startup Meati Foods.
Marinya Capital is the family office ofJohn B Fairfax from the Australian Fairfax family, who originally established Fairfax Media, a large media company. Marinya largely invests in property and agricultural businesses but has also made at least two investments in tech startups and in an Australian VC. Its most recent disclosed investments were in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein using fermentation and CO2 and other emissions, and in the $55m Series B round of Australia’s premier plant-based brand v2food in 2020.
Marinya Capital is the family office ofJohn B Fairfax from the Australian Fairfax family, who originally established Fairfax Media, a large media company. Marinya largely invests in property and agricultural businesses but has also made at least two investments in tech startups and in an Australian VC. Its most recent disclosed investments were in the $4.7m July 2021 seed funding round of NovoNutrients, the US-based biotech producer of alt-protein using fermentation and CO2 and other emissions, and in the $55m Series B round of Australia’s premier plant-based brand v2food in 2020.
Nutrinsect’s cricket flour is a 100% organic alternative protein containing twice the protein of soy, with an all-purpose natural fertilizer as its byproduct.
Nutrinsect’s cricket flour is a 100% organic alternative protein containing twice the protein of soy, with an all-purpose natural fertilizer as its byproduct.
Co-founder of Xampla
Tuomas Knowles is co-founder of Britain’s Xampla, producer of plant-based biodegradable plastics made from protein, which was founded in 2018 based on his team’s pioneering research. Knowles is a professor of physical chemistry and biophysics at Cambridge University, where he has worked since 2010 and manages the Knowles Lab which focuses on researching protein self-assembly underlying neurodegenerative disorders like Alzheimer's and Parkinson's disease. Knowles holds a PhD in Biophysics from the University of Cambridge and a degree in physics from ETH Zurich, a science and technology university.
Tuomas Knowles is co-founder of Britain’s Xampla, producer of plant-based biodegradable plastics made from protein, which was founded in 2018 based on his team’s pioneering research. Knowles is a professor of physical chemistry and biophysics at Cambridge University, where he has worked since 2010 and manages the Knowles Lab which focuses on researching protein self-assembly underlying neurodegenerative disorders like Alzheimer's and Parkinson's disease. Knowles holds a PhD in Biophysics from the University of Cambridge and a degree in physics from ETH Zurich, a science and technology university.
Animal AgTech Innovation Summit 2021: Future of aquaculture in the US
With the US Importing over 85% of its seafood, industry experts examine how and why the country should develop a sustainable aquaculture industry
Portugal's health & medtech startups: Taking innovation and disruption to heart
Backed by local and foreign money, Portugal’s healthcare and medical technology startups are hungry to go global
In Spain, women are busy launching startups
Official data show women-led startups are on the rise in Spain. We take you to some of the biggest names in the game
Grain Meat: Focusing on whole cut plant-based meat
With its proprietary fiber weaving technique and specially-designed machinery, Wuxi-based Grain Meat aims to replicate the texture and even the grain of real meat
Future Food Asia 2021: Fireside chat with Green Monday's David Yeung
For Chinese startup Green Monday, it’s important to resonate with different local audiences by adapting to local culture and dietary habits and continuously fine-tuning existing products
Venturra Capital's Raditya Pramana interview (Part II): "We need to prioritize progress"
In part two of an interview, Indonesian VC Raditya Pramana discusses foreign investment in the local ecosystem, the qualities of startups that attract him and more
New Food Invest: Building a plant-based business in the US
With plant-based startups experiencing exponential growth but facing increasingly intense competition, experts consider the opportunities and barriers in the sector
Future Food Asia: Temasek, Continental Grain on investing in agrifood in Singapore and China
The two heavyweight investors discuss opportunities, needs and how agrifood startups can scale in Asian markets
Impact investing: Spanish startups with a cause and the ecosystem backing them
As more thought and money go into socially and environmentally responsible projects, Spanish entrepreneurs, investors and big businesses are following suit
Investing in Indonesia: The fintech companies driving a new influx of capital
With 66% of Indonesians not owning a bank account, fintech startups have come up with myriad innovative products to entice a new generation of retail investors
What Indonesia’s election could mean for startups and investors
Industry players voice their hopes, concerns and expectations as the April presidential election nears
Spanish AI startups unleash the power of virtual assistants
More Spanish deep technology firms are shifting the paradigms in human-machine interactions, overhauling customer experience
SwissDeCode: Portable DNA test kits detect food contamination within minutes
DNAFoil, the startup’s rapid and accurate on-site food safety testing kit, can be deployed by non-expert staff after a few hours of training, with no need for lab equipment
Indonesia's Green Rebel Foods to take its Asian-inspired plant-based meat regional
F&B veteran duo behind the Burgreens spinoff plans Series A fundraising by end-2021 for manufacturing and regional expansion
Spain's 3D printing revolution to drive various sectors' growth
From medical splints to meat-free burgers, multimillion-dollar 3D tech hubs are spawning new verticals across Spain
Sorry, we couldn’t find any matches for“Alt-protein”.
POPULAR DATABASE
